Taisho Pharmaceutical Holdings Co., Ltd. (TAIPY) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Drug Manufacturers - Specialty & Generic Branche. Der Hauptsitz des Unternehmens ist in Tokyo, Japan. Der aktuelle CEO ist Akira Uehara.
TAIPY hat IPO-Datum 2021-01-08, 8,784 Vollzeitbeschäftigte, gelistet an der Other OTC, eine Marktkapitalisierung von $18.13B.
Taisho Pharmaceutical Holdings Co., Ltd. is a Japan-based pharmaceutical company founded in 1912 that researches, develops, manufactures, and distributes both over-the-counter (OTC) and prescription pharmaceutical products across domestic and international markets. The company operates through two main segments: the Self-Medication Operation Group, which offers OTC drugs, quasi-drugs, and consumer health products including the Lipovitan energy drink series, Pabron cold remedies, RiUP hair treatment products, and internationally recognized brands such as VICKS and Tempra; and the Prescription Pharmaceutical Operation Group, which develops and markets ethical pharmaceutical products for conditions including osteoporosis, diabetes, infections, and pain management. Beyond pharmaceuticals, Taisho engages in real estate leasing, facility management, and hotel operations, while also supplying raw materials, health foods, and skincare products. The company maintains its headquarters in Tokyo and continues to develop new therapies in therapeutic areas such as central nervous system diseases, infectious diseases, and metabolic disorders.
